Back

Safety and effectiveness of Sacubitril-Valsartan in a real-world population.

22 May 2022 (08:30 - 19:45)
Organised by:
Congress Presentation Part of: Heart Failure ePosters - focus on Chronic Heart Failure 5 Pharmacotherapy HFA Premium Access Heart Failure 2022

About the speaker

Photo
Doctor Mariana Tinoco

Alto Ave Hospital Center, Guimaraes (Portugal)

32 More presentations in this session

Presentation thumbnail
Comparison 8 vs. 10mm fenestration size of the atrial flow regulator in patients with heart failure with reduced and preserved ejection fraction: an analysis of the Prelieve Trial
Doctor C. Paitazoglou (Luebeck, DE)
Abstract Slides
Presentation thumbnail
HDAC6 inhibition reduces cardiac fibrosis, enhances mitochondrial function and demonstrates comparable efficacy as empagliflozin in a mouse model of heart failure with preserved ejection fraction
Mr J. Yang (South San Francisco, US)
Abstract Slides
Presentation thumbnail
Improved vascular function after ventricular assist device implantation
Doctor D. Nebunu (Zurich, CH)
Abstract Slides
Presentation thumbnail
Left-heart reverse remodeling patterns following treatment with sacubitril/valsartan
Doctor A. Abboud (Boston, US)
Abstract Slides
Presentation thumbnail
Identifying distinct clinical subgroups in heart failure with mildly reduced ejection fraction
Assistant Professor A. Uijl (Amsterdam, NL)
Abstract Slides

Access the full session

Session thumbnail
Heart Failure ePosters - focus on Chronic Heart Failure 5

The Event

Event poster

Heart Failure 2022

22 May 2022 08:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources